Clinical Trial Update: Study of Everolimus and Low-dose Cyclophosphamide in Patients With Metastatic Renal Cell Cancer [Phase 1, Phase 2]

View source ↗

Summary

A completed Phase 1/2 study evaluating the combination of everolimus and low-dose cyclophosphamide in patients with metastatic renal cell carcinoma.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Renal Cell Carcinoma

Drugs mentioned

• CYCLOPHOSPHAMIDE (Cyclophosphamide)
• Everolimus (everolimus)

Snippet

Sponsor: Hans J. van der Vliet, MD, PhD | Conditions: Metastatic Renal Cell Cancer | Phase 1, Phase 2 | Status: COMPLETED